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Obesity is one of themost important health risks of ourtime. The prevalence of obesity has increased
worldwide since themid1970s.According to theNational
Health and Nutrition Examination Survey, obesity af-
fected 32.2% of adults in 2003–2004 and reached a peak
in subjects in the fifth decade of life (1). Obesity is asso-
ciated with an increased risk of diabetes, dyslipidemia,
kidney disease, cardiovascular disease, all-cause mortal-
ity, and cancer (1). Thus, severe obesity is an important
cause of premature mortality among middle-aged adults
(2).Moreover, obesity, especially central obesity, is linked
to many endocrine abnormalities (3), including thyroid
dysfunction (4). This is not surprisingbecauseT3 regulates
energy metabolism and thermogenesis and plays a critical
role in glucose and lipid metabolism, food intake, and the
oxidation of fatty acids (4).
Thyroid Dysfunction and Body Weight
Thyroid dysfunction is associated with changes in body
weight and composition, body temperature, and total and
resting energy expenditure independently of physical ac-
tivity. Moreover, weight gain often develops after treat-
ment of thyroid dysfunction (5). Both subclinical and
overt hypothyroidism are frequently associated with
weight gain, decreased thermogenesis, and metabolic rate
(5, 6). In a recent cross-sectional, population-based study
of 27,097 individuals above 40 yr of age with body mass
index (BMI) of at least 30.0 kg/m2, subclinical and overt
hypothyroidismcorrelatedwith ahigherBMIandahigher
prevalence of obesity in both smokers and nonsmokers
(6). It has been noted that small variations in serum TSH
caused byminimal changes in L-T4 dosage during replace-
ment therapy are associatedwith significantly altered rest-
ing energy expenditure in hypothyroid patients (7). These
studies support the clinical evidence thatmild thyroid dys-
function is linked to significant changes in body weight
and likely represents a risk factor for overweight and
obesity.
Relationship between TSH and Body
Weight among Euthyroid Individuals
Evidence suggests that slight variations in thyroid func-
tion, even as indicated by tests that are within laboratory
reference ranges, contribute to the development of re-
gional obesity and the tendency to gain weight (8, 9), al-
though this has not been confirmed by all studies (10).
Furthermore, BMI has been negatively associated with se-
rum free T4 (FT4) (8), and fat accumulation has been as-
sociated with lower FT4 (8, 11) and higher TSH levels
among slightly overweight euthyroid individuals (4, 8, 9,
11), thereby resulting in a positive correlation between
TSH and the progressive increase in weight with time (9).
Fat cells produce leptin and are thus considered an ac-
tive endocrineorgan (4, 12).The correlationbetweenTSH
andBMI could bemediated by leptin produced by adipose
tissue. Leptin physiologically regulates energy homeosta-
sis by informing the central nervous system about adipose
tissue reserves (4). It modulates the neuroendocrine and
behavior responses to overfeeding, thereby regulating
food intake and energy expenditure. Leptin is also an im-
portant neuroendocrine regulator of the hypothalamic-
pituitary-thyroid axis (12, 13) by regulation of TRH gene
expression in theparaventricular nucleus, andTSH in turn
will stimulate leptin secretion by human adipose tissue
(13–15). Leptin also affects thyroid deiodinase activities
with activation of T4 to T3 conversion (4, 16). All the
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foregoing data support the concept of an inverse relation-
ship between thyroid hormone and leptin.
In subclinical hypothyroidism, for example, altered
thyroid functionwith normal feedback regulation (FT4 at
the lower limit of normal range and increased TSH albeit
within normal range) may be the primary event that in-
duces alterations in energy expenditure with subsequent
increases in BMI and weight (4, 8). The consequent in-
crease in fat mass and in TSH values might increase serum
leptin levels.
Thyroid Function in Obese Subjects
TSH levels are at the upper limit of the normal range or
slightly increased in obese children, adolescents, and
adults and are positively correlated with BMI (17–23).
TSH seems to be positively related to the degree of obesity
(17). A positive correlation has been identified between
serum leptin and serum TSH levels in obese individuals
(17), which could reflect the positive association between
TSH and BMI reported in some individuals (4, 8, 9, 11).
Leptin, adjusted forBMI,was found to correlatewithTSH
(17), which suggests that the increase in TSH and leptin
levels in severe obesity could result from the increased
amount of fat. Thyroid hormone levels have been reported
to be normal, increased, and decreased in obese patients
(4); this discrepancy among studies probably reflects the
fact that patients were examined at different times (during
overeating or a hypocaloric diet) and may differ in degree
and type of obesity and in plasma insulin sensitivity.
Interestingly, a moderate increase in total T3 or free T3
(FT3) levels has been reported in obese subjects (19–21).
Progressive fat accumulation was associated with a par-
allel increase in TSH and FT3 levels irrespective of insulin
sensitivity and metabolic parameters (20), and a positive
association has been reported between the FT3 to FT4
ratio and both waist circumference and BMI in obese pa-
tients (20). This finding suggests a high conversion of T4
to T3 in patients with central fat obesity due to increased
deiodinase activity as a compensatory mechanism for fat
accumulation to improve energy expenditure (20).
Despite the higher plasma TSH levels, TSH receptors
are less expressed on adipocytes of obese vs. lean individ-
uals (21). This reduced TSH receptor expression might
induce down-regulation of thyroid hormone receptors
and thyroid hormone action, thereby further increasing
plasma TSH and FT3 concentrations and constituting a
condition of peripheral thyroid hormone resistance (21).
This sequence of events would be reversed by weight loss,
which restores the size and function of mature adipocytes
(21).Aberrant thyroid functionandTSHlevel usuallynor-
malize after weight loss whether consequent to diet or to
bariatric surgery (19–23). Weight loss induces a signifi-
cant reduction in both TSH and FT3 (19–23), thereby
increasing rT3 due to reduced 5-deiodination. The de-
crease in T3 levels during weight loss with continued ca-
loric deprivation reduces energy expenditure. Therefore,
decreased T3 levels may be responsible for difficulties in
maintaining or further decreasing weight loss (23). The
finding that TSH, FT3, and leptin levels are increased in
obese subjects and that weight loss leads to decreased se-
rum TSH, FT3, and leptin levels supports the hypothesis
that the alteration in thyroid function observed in obese
subjects is reversible by losing weight (24).
Whatever the mechanism underlying elevated TSH in
obesity, it is difficult to identify obese subjects who are
affected bymild thyroid hormone deficiency. It seems rea-
sonable to suggest that hypothyroidism should be sus-
pected in obese subjects with slightly increased TSH levels
only after measuring plasma levels of thyroid hormones
and thyroid autoantibodies, and after having detected ev-
idence of impaired thyroid hormone activity at a tissue
level. Thyroid hormone deficiency can be excluded in
obese subjects with high serum TSH in the case of FT3
levels that are at the upper limit of the normal range or
slightly higher, especially in the presence of normal pe-
ripheral parameters of thyroid hormone action (e.g. lipid
profile thatwould be expected to be particularly deranged
in obese patients with thyroid hormone deficiency) (19,
25). Furthermore, in this condition, the association with
normal thyroid autoantibodiesmayhelp exclude even fur-
ther the presence of mild thyroid dysfunction and its po-
tential progression to overt disease.
The evaluation of the thyroid structure by ultrasound
does not help to diagnose hypothyroidism in obese pa-
tients (18, 26). In fact, in obese children and adults, the
moderate increase in TSH is frequently associated with an
increase in thyroid volume and hypoechogeneity with an
ultrasound pattern suggestive of Hashimoto thyroiditis,
even in the absenceof thyroidautoantibodies (18, 26).The
increased hypoechogenicity in obese subjects has been
linked to cytokines and other inflammatory markers pro-
ducedby adipose tissue. These cytokines can increaseTSH
levels (thereby increasing thyroid size) and can induce va-
sodilatation and increase permeability of thyroid vessels
with increased parenchymal inhibition (via imbibition) of
the thyroid gland that might be responsible for the hypo-
echogenicity at ultrasound (18). Interestingly, median
TSH was reported to be higher in overweight/obese pa-
tients with hypoechogenicity than in those with a normal
ultrasound pattern (26). In this regard, it is important to
recall that an ultrasound pattern suggestive of Hashimoto
thyroiditis may precede antithyroid peroxidase antibody
(TPOAb) positivity in autoimmune thyroid disease (27),
J Clin Endocrinol Metab, August 2010, 95(8):3614–3617 jcem.endojournals.org 3615
and TPOAb may not be detected in more than 20% of
individuals with ultrasound evidence of thyroid autoim-
munity (27).
There is some debate about the link between obesity
and the risk of autoimmune thyroid dysfunction (AITD),
which is the main cause of hypothyroidism in adults. The
prevalence of AITD in obesity has been reported to be
12.4% in children and between 10 and 60% in adults (25,
28). This discrepancy may be due to such factors as sex,
age, menopausal status, smoking habit, environmental
factors, iodine intake, and degree of obesity.
In this issue of JCEM, Marzullo et al. (28) address the
intriguing hypothesis of a link between obesity, leptin,
autoimmunity, and hypothyroidism. They estimated the
prevalence and characteristics of thyroid autoimmunity in
a population of obese men and premenopausal obese
women and found that leptin increases susceptibility to
AITD by regulating immune processes. As much as 69%
of their patients had severe obesity (BMI 40 kg/m2), and
the prevalence of hypothyroidism was higher in obese pa-
tients than in a control group of age- and sex-matched
subjects with normal BMI (P  0.05), as documented by
lower FT3 and FT4 plasma levels (P  0.01) and a de-
ranged lipid profile.
AITD patients (i.e. positive TPOAb) were mostly se-
verely obese (BMI  40 kg/m2) (68%; 2  5.04; P 
0.05),with nonsignificantly higherTSH levels thanAITD-
negative patients. Leptin levels were higher in AITD-pos-
itive obese patients than in AITD-negative patients, and
the prevalence of AITD was higher in patients with leptin
levels above a median of 33.8 g/liter (24 vs. 8.6%; P 
0.01). Logistic regression analysis revealed an association
between AITD and leptin (r 0.26; P  0.001) that was
unrelated to either fat body mass or BMI (P  0.001).
Multiple logistic regression analysis in pooled groups
identified female sex and leptin as significant predictors of
AITD (28).
Based on these data, one may envisage a link between
obesity, TSH increase, leptin increase, autoimmunity, al-
terations in thyroid morphology and structure, and de-
velopment of subclinical and overt hypothyroidism.
The onset of thyroid hormone deficiency, especially the
subclinical form, may go undiagnosed in obese patients.
Consequently, these patients will continue to increase in
weight and will develop a deranged lipid profile, thereby
bringing the thyroid/obesity association to a full circle.
Recent studies suggest that a higher BMI is associated
with an increased risk of thyroid cancer (29).Moreover, a
serum TSH in the upper half of the normal range is con-
sidered as an independent predictor for the presence of
thyroid cancer in thyroid nodules (30, 31). Both of these
findings together suggest that the higher serumTSH levels
could be responsible for the development of thyroid ma-
lignancy in obese patients.
Conclusions
It is important to note that the increased prevalence of
obesity worldwidemay further confound the definition of
the normal TSH range in population studies. More re-
search is necessary to determinewhethermild thyroid hor-
mone deficiency and the consequent mild TSH increase,
i.e. to the upper limit of the reference range, are involved
in the development of obesity. Moreover, studies are re-
quired to establish the potential role of high leptin levels in
increasing susceptibility to thyroid autoimmunity, which
in turn entails a high risk of developing subclinical or overt
hypothyroidism.
Obesity and thyroid dysfunction are common diseases,
and consequently clinicians should be particularly alert to
thepossibility of thyroiddysfunction inobesepatients.On
the other hand, although thyroid hormones have been in-
appropriately and frequently used in attempts to induce
weight loss in obese euthyroid subjects, there is no indi-
cation for their administration to control body weight ex-
cept in obese hypothyroid subjects. In fact, long-term
treatment with thyroid hormones does not significantly
improveweight loss in obese subjectswithout thyroid dys-
function and, on the contrary, will entail a risk of adverse
effects (32). It is conceivable that selected thyroid analogs
might be a means by which to improve weight loss by
increasing energy expenditure (as well as improving lipid
profiles) in obese patients with low T3 during continued
caloric deprivation (33).
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